title: Validation of the heat treatment step used in the production of diaspirin crosslinked hemoglobin (DCLHb) for viral inactivation.
abstract: A series of experiments was performed to assess the ability of the heat treatment step used in the manufacture of diaspirin crosslinked hemoglobin (DCLHb) to inactivate viruses. In-process solutions (reaction mixtures after the crosslinking process) from six different manufacturing lots were used as test media in a 1:680 scaled down system in which the key process parameters used in the large scale production were duplicated. The inactivation of five different viruses (Bovine Viral Diarrhea Virus, Pseudorabies Virus, Human Immunodeficiency Virus 1, Porcine Parvovirus and Hepatitis A Virus) was evaluated. Each validation experiment consisted of spiking the solution at 37 degrees C with virus, heating to 74 +/- 1 degrees C over a period of 30 minutes, holding at 74 +/- 1 degrees C for 90 minutes and cooling from 74 +/- 1 degrees C to less than 10 degrees C over a period of 30 minutes. Duplicate experiments were performed with each of the viruses with the exception of Human Immunodeficiency Virus 1, for which three experiments were performed. In each experiment samples were removed before, during, and after heating for the purpose of determining virus titer and evaluating key process parameters. The results obtained from these experiments confirmed that the key process parameters in these experiments using the scaled down test system reproduced those of the large scale manufacturing process. The results of the virus assays showed at least a 7 log reduction was accomplished by the heat treatment for each of the viruses tested.
authors.affiliation: Blood Substitutes Program, Baxter Healthcare Corporation, Round Lake, Illinois 60073, USA.
authors.forename: M
authors.initials: M
authors.lastname: Azari
authors.forename: A
authors.initials: A
authors.lastname: Ebeling
authors.forename: R
authors.initials: R
authors.lastname: Baker
authors.forename: K
authors.initials: K
authors.lastname: Burhop
authors.forename: T
authors.initials: T
authors.lastname: Camacho
authors.forename: T
authors.initials: T
authors.lastname: Estep
authors.forename: S
authors.initials: S
authors.lastname: Guzder
authors.forename: T
authors.initials: T
authors.lastname: Marshall
authors.forename: K
authors.initials: K
authors.lastname: Rohn
authors.forename: R
authors.initials: R
authors.lastname: Sarajari
mesh_terms: D000818:Animals; D001241:Aspirin / Q000009:adverse effects / Q000031:analogs & derivatives*; D001802:Blood Substitutes / Q000009:adverse effects; D001908:Diarrhea Viruses, Bovine Viral / Q000254:growth & development; D006678:HIV / Q000254:growth & development; D006454:Hemoglobins / Q000009:adverse effects; D006507:Hepatovirus / Q000254:growth & development; D011558:Herpesvirus 1, Suid / Q000254:growth & development; D006358:Hot Temperature; D006801:Humans; D017992:Parvovirus / Q000254:growth & development; D015203:Reproducibility of Results; D013242:Sterilization / Q000379:methods; D013552:Swine; D014775:Virus Activation
chemical_list: D001802:Blood Substitutes; D006454:Hemoglobins; C083478:diaspirin-cross-linked hemoglobin; D001241:Aspirin